Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD
Clinical Journal of the American Society of Nephrology · 2026-11 · 21 (11) · 1879-1888
DOI: 10.2215/cjn.0000001168 ↗Abstract
Key Points Romosozumab was associated with lower vertebral fracture risk than teriparatide in patients with osteoporosis and CKD. No significant differences were observed in nonvertebral or hip fracture risk between treatment groups. Romosozumab was associated with lower risks of major adverse cardiovascular events and myocardial infarction compared with teriparatide. Background Osteoporosis commonly coexists with CKD, increasing skeletal fragility and cardiovascular risk. While romosozumab shows superior fracture prevention in general osteoporosis, evidence in CKD stages 3–5 patients remains limited. Methods Using a target trial emulation design, we conducted a retrospective cohort study leveraging the TriNetX US research network. Patients aged 40 years or older with osteoporosis and an eGFR
EUVIMED